Advertisement

2019 ASCO: Sexual Harassment and Gender Disparities: Survey of Gynecologic Oncologists

Advertisement

Key Points

  • Some form of sexual harassment during training or practice was experienced by 64% of all respondents—71% of women and 51% of men. Only 10% reported the incident(s) to officials—17% of women and 10% of men.
  • The most frequent forms of sexual harassment experienced by those in training or practice were being subjected to sexist remarks, being denied opportunities for training, unwanted sexual advances, and being asked to exchange sexual favors for academic positions.
  • About 34% of women stated that gender had affected their career advancement, compared with 10% of men, and 42% of women stated that gender played a role in setting their salary, compared with 6% of men.

A recent survey of U.S.-based physician members of the Society of Gynecologic Oncology found that 64% of respondents experienced sexual harassment in training or practice; among women, the rate was 71% and among men, it was 51%. Only 10% reported the incident(s) to officials. In addition, women were more likely than men to respond that gender affected career advancement (34% vs 10%) and played a role in setting their salary (42% vs 6%). The study was presented by Stasenko et al the 2019 ASCO Annual Meeting (Abstract LBA10502).

“The topic of sexual harassment has been widely discussed in the media as it applies to the movie, music, and sports industries, but conversation in the medical community has largely been limited to personal anecdotes discussed behind closed doors,” said lead study author Marina Stasenko, MD, of Memorial Sloan Kettering Cancer Center, New York. “Gender disparities have persisted in medicine despite a growing number of female physicians, and through our study, we hope to increase awareness and acknowledgment of sexual harassment and gender inequalities within gynecologic oncology, hopefully leading to future interventions to address these disparities.”

About the Survey

The study was designed to evaluate perceived gender biases, the prevalence of sexual harassment in training and the workplace, and the impact of gender and harassment on career growth and advancement. It was modeled, in part, on an Association of American Medical Colleges survey on this topic that has been conducted since 2012.

The anonymous survey was sent in October 2018 to all 1,566 U.S.-based Society of Gynecologic Oncology members who were physicians. Of those queried, 402 (26%) replied; 255 replies were from women, and 147 were from men.

Responses

Some form of sexual harassment during training or practice was experienced by 64% of all respondents—71% of women and 51% of men. Only 10% reported the incident(s) to officials—17% of women and 10% of men, although the difference is not statistically significant. The most common reasons for not reporting sexual harassment incident(s) to officials were that respondents thought the incident(s) did not seem important enough (40%) or that nothing would be done about it (37%), and fear of retaliation (34%).

The most frequent forms of sexual harassment experienced by those in training or practice, respectively, were being subjected to sexist remarks (58%/51% of women and 28%/24% of men); being denied opportunities for training (26%/33% of women and 17%/19% of men); unwanted sexual advances (30%/23% of women and 27%/28% of men); and being asked to exchange sexual favors for academic positions (4% of women and 2% of men, equally in training and practice).

Additional survey findings included:

  • 31% of women and 14% of men said they received lower evaluations or academic positions as a result of harassment
  • 34% of women stated that gender had affected their career advancement, compared with 10% of men
  • 42% of women stated that gender played a role in setting their salary, compared with 6% of men
  • 57% of women perceived a gender pay gap, compared with 9% of men.

Dr. Stasenko noted that she hopes this study leads to a larger conversation about sexual harassment in the medical field and serves as a launchpad for further action.

Disclosure: This study was funded by Memorial Sloan Kettering Cancer Center. For full disclosures of the study authors, visit coi.asco.org.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement




Advertisement